Aufderklamm Stefan, Aicher Wilhelm Karl, Amend Bastian, Stenzl Arnulf
Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.
Curr Opin Urol. 2019 Jul;29(4):394-399. doi: 10.1097/MOU.0000000000000624.
Stress urinary incontinence (SUI) is one of the most prevalent disorders of the lower urinary tract. Actual standard conservative and surgical therapeutic modalities are offering a symptomatic relief without treating the underlying disorder. Therefore, advances in cell-based regenerative medicine have implemented the use of autologous cells with the aim to treat urinary incontinence.
Different types of cells have been investigated to regain the function of the rhabdosphincter muscle in the urethral closure complex: myogenic progenitor cells, adipose tissue-derived stromal cells and mesenchymal stromal cells were mostly applied. Many of the preclinical studies published success of cell therapies. However, most clinical studies included only a few patients and rather short periods of follow-up. Furthermore, different cell types as well as injection techniques were used.
The use of stem cells seems to be a feasible and safe technique with promising results in patients with SUI. However, as a result of heterogeneity of preclinical and clinical trials, the best approach to cell-based therapy in SUI is still under investigation. The definition of the optimal cell type applied for the regeneration of the sphincter, the development of surgical injection advices and adequate tools for the investigation of the muscle regeneration during the follow-up have to be investigated to improve the use of autologous cells in the therapy of SUI.
压力性尿失禁(SUI)是下尿路最常见的疾病之一。目前的标准保守和手术治疗方式只能缓解症状,而无法治疗潜在疾病。因此,基于细胞的再生医学进展已开始使用自体细胞来治疗尿失禁。
人们研究了不同类型的细胞,以恢复尿道闭合复合体中横纹括约肌的功能:主要应用了肌源性祖细胞、脂肪组织来源的基质细胞和间充质基质细胞。许多临床前研究报道了细胞治疗的成功案例。然而,大多数临床研究仅纳入了少数患者,且随访时间较短。此外,使用了不同的细胞类型和注射技术。
干细胞治疗似乎是一种可行且安全的技术,对SUI患者有很有前景的治疗效果。然而,由于临床前和临床试验的异质性,SUI基于细胞治疗的最佳方法仍在研究中。为了改善自体细胞在SUI治疗中的应用,必须研究用于括约肌再生的最佳细胞类型的定义、手术注射建议的制定以及随访期间肌肉再生研究的适当工具。